CardioThoracic Systems Looking To Break Even In Fourth Quarter 1999
This article was originally published in The Gray Sheet
Executive Summary
CardioThoracic Systems' forecast of breaking even by year-end is based on increasing physician acceptance of minimally invasive cardiac surgery products in the second quarter and additional approvals expected in the latter half of the year, CEO Richard Ferrari told analysts during a July 21 teleconference.
You may also be interested in...
COVID-19 Vaccines Are Coming Soon, But Therapeutics Needed Now
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.
Pfizer Holds Number One Spot And Takeda Breaks The Top 10
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.
Indoco Counts On Indian Market Bouncing Back
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: